The Role of Gut Microbiota in Type 2 Diabetes: From Dysbiosis to Therapeutic Opportunities—A literature review

Growing evidence highlights the gut microbiota as a critical regulator of host metabolism. In type 2 diabetes (T2D), disturbances in microbial composition are increasingly recognized as contributors to insulin resistance, chronic inflammation, and metabolic dysregulation. This review aims to summarize the current understanding of gut microbiota alterations in T2D, their underlying mechanisms, clinical relevance, and potential therapeutic strategies. A literature review was conducted using MEDLINE and SCOPUS databases, with the focus on keywords including “type 2 diabetes,” “gut microbiota,” “dysbiosis,” “short-chain fatty acids,” “intestinal permeability,” “inflammation,” “metabolic endotoxemia,” “probiotics,” “prebiotics,” “synbiotics,” “postbiotics,” and “fecal microbiota transplantation.” Articles published between 2015 and 2025 were considered, with preference given to peer-reviewed original research and systematic reviews. To ensure completeness, additional studies were identified through manual screening of reference lists in key publications, allowing the inclusion of both mechanistic and clinical perspectives relevant to type 2 diabetes and gut microbiota. Type 2 diabetes is linked to reduced gut microbiota diversity, with lower levels of short-chain fatty acid (SCFA) producers such as Faecalibacterium prausnitzii and Roseburia, and higher abundance of pro-inflammatory species including Ruminococcus gnavus and Bacteroides. These alterations are associated with impaired glucose control, elevated glycated hemoglobin (HbA1c), unfavorable lipid profiles, and increased inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6). Diet, lifestyle, medications, and microbiota-targeted interventions can modulate these microbial changes. While probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation hold therapeutic potential, further standardized and large-scale studies are required to establish clinical effectiveness and support personalized treatment strategies.

Authors

Institutions

Publication Details

Journal
Bratislavské lekárske listy/Bratislava medical journal
Published
2026-04-06
DOI
https://doi.org/10.1007/s44411-026-00596-0
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of Gut Microbiota in Type 2 Diabetes: From Dysbiosis to Therapeutic Opportunities—A literature review

Anna Maria Różańska-Walędziak, Joanna Cielecka, Maciej Walędziak
Bratislavské lekárske listy/Bratislava medical journal
Gut microbiota and health
article

The Role of Gut Microbiota in Type 2 Diabetes: From Dysbiosis to Therapeutic Opportunities—A literature review

Anna Maria Różańska-Walędziak, Joanna Cielecka, Maciej Walędziak
article en

Abstract

Growing evidence highlights the gut microbiota as a critical regulator of host metabolism. In type 2 diabetes (T2D), disturbances in microbial composition are increasingly recognized as contributors to insulin resistance, chronic inflammation, and metabolic dysregulation. This review aims to summarize the current understanding of gut microbiota alterations in T2D, their underlying mechanisms, clinical relevance, and potential therapeutic strategies. A literature review was conducted using MEDLINE and SCOPUS databases, with the focus on keywords including “type 2 diabetes,” “gut microbiota,” “dysbiosis,” “short-chain fatty acids,” “intestinal permeability,” “inflammation,” “metabolic endotoxemia,” “probiotics,” “prebiotics,” “synbiotics,” “postbiotics,” and “fecal microbiota transplantation.” Articles published between 2015 and 2025 were considered, with preference given to peer-reviewed original research and systematic reviews. To ensure completeness, additional studies were identified through manual screening of reference lists in key publications, allowing the inclusion of both mechanistic and clinical perspectives relevant to type 2 diabetes and gut microbiota. Type 2 diabetes is linked to reduced gut microbiota diversity, with lower levels of short-chain fatty acid (SCFA) producers such as Faecalibacterium prausnitzii and Roseburia, and higher abundance of pro-inflammatory species including Ruminococcus gnavus and Bacteroides. These alterations are associated with impaired glucose control, elevated glycated hemoglobin (HbA1c), unfavorable lipid profiles, and increased inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6). Diet, lifestyle, medications, and microbiota-targeted interventions can modulate these microbial changes. While probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation hold therapeutic potential, further standardized and large-scale studies are required to establish clinical effectiveness and support personalized treatment strategies.

Bratislavské lekárske listy/Bratislava medical journal
National Academy of Medicine (US), Cardinal Stefan Wyszynski University in Warsaw (PL)
Zero hunger
Openalex Percentile: Top 21%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.